Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.

Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clin Cancer Res (2015) 1.80

Rekindling cancer vaccines. Nat Biotechnol (2016) 1.39

Therapeutic cancer vaccines. J Clin Invest (2015) 1.23

The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. Biomark Cancer (2016) 0.92

Dendritic cell-based immunotherapy. Cell Res (2016) 0.81

Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat Commun (2017) 0.81

Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. Core Evid (2014) 0.81

What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence. Ther Adv Urol (2016) 0.81

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. Clin Med Insights Oncol (2016) 0.80

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines (Basel) (2016) 0.78

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. Oncoimmunology (2015) 0.78

Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res (2016) 0.78

Immune Therapy for Prostate Cancer. Cancer J (2016) 0.76

Synergistic immunologic targets for the treatment of prostate cancer. Exp Biol Med (Maywood) (2016) 0.76

Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology (2016) 0.76

TCR diversity - a universal cancer immunotherapy biomarker? J Immunother Cancer (2016) 0.75

Immunotherapy in genitourinary malignancies. Curr Opin Urol (2016) 0.75

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer (2016) 0.75

Prospects in the Application of Photodynamic Therapy in Oral Cancer and Premalignant Lesions. Cancers (Basel) (2016) 0.75

3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data. BMC Bioinformatics (2017) 0.75

Immune Checkpoint Therapies in Prostate Cancer. Cancer J (2016) 0.75

Evaluating immune responses after sipuleucel-T therapy. Cancer Biol Ther (2015) 0.75

Rush hour traffic: directing T cells to tumor. J Natl Cancer Inst (2014) 0.75

Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy. Nat Rev Urol (2017) 0.75

Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer. Int J Mol Sci (2017) 0.75

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75

Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72

The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol (2005) 4.40

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res (2009) 3.83

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol (2009) 3.51

Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res (2012) 2.23

Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol (2013) 2.08

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother (2012) 1.82

12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep (2012) 1.81

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol (2001) 1.46

Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res (2005) 1.45

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res (2011) 1.42

Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology (2013) 1.35

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31